SC
ABBV icon

Swan Capital’s AbbVie ABBV Stock Holding History

Swan Capital’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.79K Buy
+23
New +$4.95K ﹤0.01% 246
2026
Q1 		– Sell
-52
Closed -$11.9K – 552
2025
Q4 		$11.9K Buy
+52
New +$11.8K ﹤0.01% 160
2025
Q3 		– Sell
-30
Closed -$5.57K – 492
2025
Q2 		$5.57K Buy
+30
New +$5.58K ﹤0.01% 221

Other funds holding ABBV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Swan Capital's ABBV Position: Q2 2026 in Review

Swan Capital opened a new position in AbbVie (ABBV) in Q2 2026: 23 shares worth $5.79K. The stake represents ﹤0.01% of the portfolio and ranks #246 among its holdings. This is a return to the name: Swan Capital previously reported a position in ABBV as recently as Q4 2025.

Swan Capital first reported a position in ABBV in Q2 2025 and has held it in 3 quarters since. The position peaked at $11.9K in Q4 2025. 4,215 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Swan Capital held 23 shares of AbbVie worth $5.79K as of Q2 2026.
  • AbbVie was a new Swan Capital position in Q2 2026.
  • AbbVie made up ﹤0.01% of Swan Capital's portfolio in Q2 2026, its #246 holding.
  • Swan Capital first reported a position in AbbVie in Q2 2025 and has held it in 3 quarters since.
  • Swan Capital's AbbVie position peaked at $11.9K in Q4 2025.
  • 4,215 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Swan Capital's 13F filing for Q2 2026, filed 13 Aug 2026.